Tenaya Therapeutics Secures $106 Million in Series C Funding to Accelerate Pipeline of Potentially Curative Therapies for Heart Disease

02 Mar, 2021

Tenaya Therapeutics Secures $106 Million in Series C Funding to Accelerate Pipeline of Potentially Curative Therapies for Heart Disease
Photo by Ilya Pavlov on Unsplash

– Tenaya Therapeutics secured $106m in Series C funding.
– The round was led by RTW Investments, LP and adds new investors RA Capital Management, Fidelity Management & Research Company and funds and accounts advised by T. Rowe Price Associates, Inc.
– The new funding will allow Tenaya to advance its lead gene therapy program towards clinical studies; progress new programs towards IND-enabling studies; build on existing drug discovery and development capabilities across its three platforms; and invest in cGMP manufacturing capabilities.

Biopharma Biotechnology Health Care North America Therapeutics
Crunchbase icon

Content report

The following text will be sent to our editors: